Treatment of glomerulonephritis in systemic disease

  • Wai Y. Tse
  • D. Adu
Part of the Developments in Nephrology book series (DINE, volume 40)


The overall survival of patients with systemic lupus erythematosus (SLE) and nephritis has improved considerably over the past few decades [1, 2, 3, 4, 5, 6, 7, 8] (Table 8.1). This improved survival is probably due to a combination of the wider use of corticosteroids and immunosuppressants, together with the availability of more effective antihypertensive drugs and antibiotics. Thus early deaths from extrarenal lupus and infection are now uncommon, and renal failure and cardiovascular disease have emerged as important determinants of morbidity and mortality [9, 10, 11, 12].


Systemic Lupus Erythematosus Lupus Nephritis Membranous Nephropathy Mixed Cryoglobulinemia Proliferative Glomerulonephritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pollak VE, Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Med 1964;63:537–50.Google Scholar
  2. 2.
    Baldwin DS, Lowenstein J, Rothfield NF, Gallo GR, McCluskey RT. The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med 1970;73:929–42.PubMedGoogle Scholar
  3. 3.
    Ponticelli C, Zucchelli P, Moroni G, Cagnoli L, Banfi G, Pascuali S. Long-term prognosis of diffuse lupus nephritis. Clin Nephrol 1987;28, 263–71.PubMedGoogle Scholar
  4. 4.
    Nossent HC, Henzen-Logmans SC, Vroom TM, Berden JHM, Swaak TJG. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum 1990;33:970–7.Google Scholar
  5. 5.
    Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol 1994;8:230–49.PubMedGoogle Scholar
  6. 6.
    Donadio JV, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995;4:109–15.PubMedGoogle Scholar
  7. 7.
    Neumann K, Wallace DJ, Azen C et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995;25:47–55.PubMedGoogle Scholar
  8. 8.
    Moroni, G Quaglini S, Maccario M, Banfi G, Ponticelli C. ‘Nephritic flares’ are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047–53.PubMedGoogle Scholar
  9. 9.
    Abeles M, Urman JD, Weinstein A, Lowenstein M, Rothfield NF. Systemic lupus erythematosus in the younger patient: survival studies. J Rheum 1980;7:515–22PubMedGoogle Scholar
  10. 10.
    Ginzler EM, Diamond HS, Weiner M et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 1982;25: 601–11.PubMedGoogle Scholar
  11. 11.
    Nossent JC, Bronsveld W, Swaak AJG. Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:810–16.PubMedGoogle Scholar
  12. 12.
    Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Lupus nephritis: Prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992;19: 473–9.PubMedGoogle Scholar
  13. 13.
    Adu D, Cameron JS. Lupus nephritis. Clin Rheum Dis 1982;8:153–82.PubMedGoogle Scholar
  14. 14.
    McCluskey RT. Lupus Nephritis I. In: Sommers SC, editor. Kidney Pathology Decennal 1966-1975. New York: Appleton Century Crofts; 1975: 435–60.Google Scholar
  15. 15.
    Austin HA, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis: contributions of renal histology. Am J Med 1983;75:382–90.PubMedGoogle Scholar
  16. 16.
    Banfi G, Mazzucco G, Di Belgiojoso GB et al. Morphological parameters in lupus nephritis: their relevance for classification and relationship with clinical and histological findings and outcome. Q J Med 1985;55:153–68.PubMedGoogle Scholar
  17. 17.
    Leaker B, Fairley KF, Dowling J, Kincaid-Smith PS. Lupus nephritis: clinical and pathological correlatiosn. Q J Med 1987;62:163–79.PubMedGoogle Scholar
  18. 18.
    McLaughlin J, Gladman DD, Urowitz MB, Bombardier C, Farewell VT, Cole E. Kidney biopsy in systemic lupus erythematosus. II. Survival analysis according to biopsy results. Arthritis Rheum 1991;34:1268–73.PubMedGoogle Scholar
  19. 19.
    Balow JE, Boumpas DT, Austin HA et al. Renal disease. In: Schur PH, editor. The Clinical Management of Systemic Lupus Erythematosus. Philadelphia, PA: Lippincott-Raven; 1996; 109–26.Google Scholar
  20. 20.
    Balow JE, Boumpas DT, Fessier BJ, Austin HA. Management of lupus nephritis. Kidney Int 1996;53:S88–92.Google Scholar
  21. 21.
    Donadio VJ. Treatment of membranous nephropathy in systemic lupus erythematosus. Nephrol Dial Transplant 1992; 1:97–104Google Scholar
  22. 22.
    Pasquali S, Banfi G, Zucchelli G, Moroni G, Ponticelli C, Zucchelli P. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993;39:175–82.PubMedGoogle Scholar
  23. 23.
    Sloan RP, Schwartz MM, Korbet SM, Borok RZ, Lupus Nephritis Collaborative Study Group. Long-term outcome in systemic lupus erythematosus membranous glomerulonephri-tis. J Am Soc Nephrol 1996;7:299–305.PubMedGoogle Scholar
  24. 24.
    Pollak VE, Pirani CL, Dujovne I et al. The clinical course of lupus nephritis: relationship to the renal histologic findings. In: Kincaid-Smith P, Mathew TH, Becker EL, editors. Glomerulonephritis: Morphology, Natural History, and Treatment. New York: Wiley; 1973: 1167–81.Google Scholar
  25. 25.
    Sztejnbok M, Stewart A, Diamond H, Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum1971; 14:639–45PubMedGoogle Scholar
  26. 26.
    Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med 1971;75:165–71.PubMedGoogle Scholar
  27. 27.
    Donadio JV, Holley KE, Wagoner RD, Ferguson RH, McDufie FC. Treatment of lupus nephritis with prednisolone and combined prednisolone and azathioprine. Ann Intern Med 1972;77:829–35.PubMedGoogle Scholar
  28. 28.
    Cade R, Spooner G, Schlein E et al. Comparison of azathioprine, prednisolone, and heparin alone or combined in treating lupus nephritis. Nephron 1973; 10:37–56.PubMedGoogle Scholar
  29. 29.
    Donadio JV, Holley KE, Wagoner RD, Ferguson RH, McDufie FC. Further observations on the treatment of lupus nephritis with prednisolone and combined prednisolone and azathioprine. Arthritis Rheum 1974;17:573–82.PubMedGoogle Scholar
  30. 30.
    Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus nephritis. Arthritis Rheum 1974;6:923–37.Google Scholar
  31. 31.
    Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisolone compared with prednisolone alone in the treatment of systemic lupus erythematosus. Ann Intern Med 1975; 83:597–605.PubMedGoogle Scholar
  32. 32.
    Decker JL, Klippel JH, Plotz PH, Steinberg AD. Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Annal Int Med1975;83: 606–15.Google Scholar
  33. 33.
    Donadio JV, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisolone and combined prednisolone and cyclophosphamide. N Engl J Med 1978;299:1151–5.PubMedGoogle Scholar
  34. 34.
    Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 1982;96:728–36.PubMedGoogle Scholar
  35. 35.
    Carette, S, Klippel JH, Decker JL et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 1983;99:1–8.PubMedGoogle Scholar
  36. 36.
    Austin HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis: Controlled trial of prednisolone and cytotoxic drugs. N Eng J Med 1986;314: 614–19.Google Scholar
  37. 37.
    Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolone alone. Arthritis Rheum 1991;34:945–50.PubMedGoogle Scholar
  38. 38.
    Boumpas DT, Austin HA, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimes of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340: 741–5.PubMedGoogle Scholar
  39. 39.
    Sesso R, Monteiro M, Sato M, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994;3: 107–12.PubMedGoogle Scholar
  40. 40.
    Gourley MF, Austin HA, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549–57.PubMedGoogle Scholar
  41. 41.
    Austin HA, Boumpas DT. Treatment of lupus nephritis. Semin Nephrol 1996;16:527–35.PubMedGoogle Scholar
  42. 42.
    Cameron JS. Glomerular and tubular disease. The treatment of severe lupus nephritis. Nephrol 1996;2:S35–41.Google Scholar
  43. 43.
    Levitt JI. Deterioration of renal function after discontinuation of long-term prednisolone-azathioprine therapy in primary renal disease. N Engl J Med 1970;282:1125–7.PubMedGoogle Scholar
  44. 44.
    Sharon E, Kaplan D, Diamond HS. Exacerbation of systemic lupus erythematosus after withdrawal of azathioprine therapy. N Engl J Med 1972;288:122–4.Google Scholar
  45. 45.
    French Cooperative Group. A randomised trial of plasma exchange in severe acute systemic lupus erythematosus: methodology and interim analysis. Plasma Ther Transfus Technol 1985; 6:535–9.Google Scholar
  46. 46.
    Derksen RHWM, Hené RJ, Kallenberg CGM, Valentijn RM, Kater L, on behalf of the Dutch Co-operative Study Group. Prospective multicentre trial on the short-term effects of plasma exchange versus cytotoxic drugs in steroid-resistant lupus nephritis. Neth J Med 1988;33:168–77PubMedGoogle Scholar
  47. 47.
    Lewis EJ, Hunsicker LG, Lan S-P, Rohde RD, Lachin JM, for the Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992;326:1373–9.PubMedGoogle Scholar
  48. 48.
    Clark WF, Dau PC, Euler HH et al. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the Lupus Plasmapheresis Study Group trial. J Clin Apheresis 1991;6:40–7.PubMedGoogle Scholar
  49. 49.
    Euler HH, Guillevin L. Plasmapheresis and subsequent pulse cyclophosphamide in severe lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. Ann Med Interne 1994;145:296–302.Google Scholar
  50. 50.
    Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronisation of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 37:1784–94.PubMedGoogle Scholar
  51. 51.
    Pollak VE, Pirani CL, Kark RM. The effect of large doses of prednisolone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 1961;57:495–511.PubMedGoogle Scholar
  52. 52.
    Hahn BH, Bagby M, Hamilton T, Osterland CK. Comparison of therapeutic and immuno-suppressive effects of azathioprine, prednisolone and combined therapy in NZB/NZW mice. Arthritis Rheum 1973; 16:163–70.PubMedGoogle Scholar
  53. 53.
    Ginzler E, Diamond H, Guttadauria M, Kaplan D. Prednisolone and azathioprine compared to prednisolone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum 1976; 19:693–9.PubMedGoogle Scholar
  54. 54.
    Dawisha JM, Yarboro CH, Vaughan EM, Austin HA, Balow JE, Klippel KH. Outpatient monthly oral cyclophosphamide therapy in systemic lupus erythematosus. J Rheumatol 1996; 23:273–8.PubMedGoogle Scholar
  55. 55.
    Silverman JA, Pascucci VL, Chatterji DC, Klippel JH. The pharmoeokinetics of bolus oral cyclophosphamide in systemic lupus erythematosus. Arthritis Rheum1984;27:(Suppl.): S64 (abstract).Google Scholar
  56. 56.
    Elion GB, Burgi E, Hitchings GH. Studies on condensed pyrimidine systems. IX. The synthesis of some 6-substituted purines. J Am Chem Soc 1952;74: 411–14.Google Scholar
  57. 57.
    Karnofsky DA. Late effects of immunosuppressive anticancer drugs. Fed Proc 1967;26:925–32.PubMedGoogle Scholar
  58. 58.
    Balow JE, Austin HA, Tsokos GC, Antonovych TT, Steinberg AD, Klippel JH. Lupus nephritis. Ann Intern Med1987; 106:79–94.PubMedGoogle Scholar
  59. 59.
    Plotz PH, Klippel JH, Decker JL et al. Bladder complications in patients receiving cyclophosphamide and urinary bladder toxicity. Ann Intern Med1979;91:221–3.PubMedGoogle Scholar
  60. 60.
    Stillwell TJ, Benson RCJ, DeRemee RA, MacDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener’s granulomatosis. Arthritis Rheum 1988;31:465–70.PubMedGoogle Scholar
  61. 61.
    Hoffman GS, Kerr Gs, Leavitt RY et al. Wegener’s granulomatosis. An analysis of 158 patients. Ann Intern Med1992;116:488–98.PubMedGoogle Scholar
  62. 62.
    Klein NW, Vogler MA, Chatot CL, Pierro LJ. The use of cultured rat embryos to evaluate the teratogenic activity of serum. Cadmium and cyclophosphamide. Teratology 1980;21:199–208.PubMedGoogle Scholar
  63. 63.
    Trompeter RS, Evans PR, Barratt TM. Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods. Lancet 1981;i:1177–9.Google Scholar
  64. 64.
    Koyama H, Wada T, Nishizawa T et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403–9.PubMedGoogle Scholar
  65. 65.
    Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk of sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366–9.PubMedGoogle Scholar
  66. 66.
    Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995;4:11–14.PubMedGoogle Scholar
  67. 67.
    Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1972;i:568–9.Google Scholar
  68. 68.
    McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996;55:224–9.PubMedGoogle Scholar
  69. 69.
    Donadio JV, Glassock RJ. Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 1993;21:239–50.PubMedGoogle Scholar
  70. 70.
    Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisolone over prednisolone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984;311:1528–33.PubMedGoogle Scholar
  71. 71.
    Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193–9.PubMedGoogle Scholar
  72. 72.
    Verrier Jones J, Bucknall RC, Gumming RH et al. Plasmapheresis in the management of acute systemic lupus erythematosus. Lancet 1976;ii:709–11.Google Scholar
  73. 73.
    Clark WF, Balfe JW, Cattran DC et al. Long-term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis. Plasma Ther Transfus Technol 1984;5:353–60.Google Scholar
  74. 74.
    Nasca T, Muder RR, Thomas DB, Schrecker JC, Ruben FL. Antibody response to pneumococcal polysaccharide vaccine in myasthenia gravis: effect of therapeutic plasmapheresis. J Clin Apheresis 1990;5:1339.Google Scholar
  75. 75.
    Dau PC. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease. J Neuroimmunol1990;30; 15–21.PubMedGoogle Scholar
  76. 76.
    Lombardo R, Cepparrone F, Di Pietro G, Franco C, Graziani G, Avanzi G. Plasma exchange in systemic lupus erythematosus. Experience in thirty-seven patients. Int J Artif Org 1993; 16: 177–9.Google Scholar
  77. 77.
    Pirner K, Rubbert A, Burmester GR, Kalden JR, Manger B. Intravenous administration of immunoglobulins in systemic lupus erythematosus: review of the literature and initial clinical experience. Infusions Ther Transfusion Med 1993;20:131–5.Google Scholar
  78. 78.
    Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol1994; 12:163–8.PubMedGoogle Scholar
  79. 79.
    Balletta M, Sabella D, Magri P et al. Cyclosporin plus steroids versus steroids alone in the treatment of lupus nephritis. Contrib Nephrol 1992;99:129–30.PubMedGoogle Scholar
  80. 80.
    Miescher PA, Favre H, Lemoine R, Huang YP. Drug combination therapy of systemic lupus erythematosus. Springer Semin Immunopathol 1994; 16:295–311.PubMedGoogle Scholar
  81. 81.
    Radhakrishnan J, Kunis CL, D’Agati V, Appel GB. Cyclosporin treatment of lupus membranous nephropathy. Clin Nephrol 1994;42:147–54.PubMedGoogle Scholar
  82. 82.
    Walz LeBlanc BA, Dagenais P, Urowitz MB, Gladman D. Methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:836–8.PubMedGoogle Scholar
  83. 83.
    Ferraccioli GF, De Vita S, Bartoli E. Methotrexate benefits in patients with lupus with and without nephritis. J Rheumatol 1995;22:1442–7.PubMedGoogle Scholar
  84. 84.
    Prickett JD, Robinson DR, Steinberg AD. Effects of dietary enrichment with eicosapentae-noic acid upon autoimmune nephritis in female NZB × NZW/F1 mice. Arthritis Rheum 1983; 26:133–9.PubMedGoogle Scholar
  85. 85.
    Robinson DR, Prickett JD, Makoul GT, Steinberg AD, Golvin RB. Dietary fish oil reduces progression of established renal disease in NZB × NZW/F1 mice and delays renal disease in BXSB and MRL/lpr strains. Arthritis Rheum1986;29:539–46.PubMedGoogle Scholar
  86. 86.
    Endres S, Ghorbani R, Kelly VE et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265–71.PubMedGoogle Scholar
  87. 87.
    Santoli D, Zurier RB. Prostaglandins E precursor fatty acids inhibit human IL-2 production by a PGE-independent mechanism. J Immunol 1989;143:1303–9.PubMedGoogle Scholar
  88. 88.
    Das UN. Beneficial effect of eicosapentaenoic and docosahexaenoic acids in the management of systemic lupus erythematosus and its relationship to the cytokine network. Prostagland Leukotri Essent Fatty Acids 1994;51:207–13.Google Scholar
  89. 89.
    Westberg G, Tarkowski A. Effect of MAXEPA in patients with SLE. Scand J Rheumatol 1990;19:137–43.PubMedGoogle Scholar
  90. 90.
    Lahita RG. Sex, age, and systemic lupus erythematosus. In: Lahita RG, editor. Systemic Lupus Erythematosus. New York: Churchill Livingstone; 1992.Google Scholar
  91. 91.
    Mund, A, Swison J, Rothfield N. Effect of pregnancy on the course of systemic lupus erythematosus. J Am Med Assoc 1963; 183:917–25.Google Scholar
  92. 92.
    Jungers, P, Dougados M, Pelissier C et al. Influence of oral contraceptive therapy on activity of systemic lupus erythematosus. Arthritis Rheum1982;25:618–23.PubMedGoogle Scholar
  93. 93.
    Melez, KA, Boegel WA, Steinberg AD. Therapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females of different ages. Arthritis Rheum 1980;241–8.Google Scholar
  94. 94.
    Steinberg AD, Roths JB, Murphy ED. Effects of thymectomy and androgen administration upon the autoimmune disease of MRL/Mo-lpr/lpr mice. J Immunol 1980;125:871–83.PubMedGoogle Scholar
  95. 95.
    Sthoeger ZM, Bentwich ZVI, Zinger H, Mozes E. The beneficial effect of the estrogen antagonist, tamoxifen on experimental systemic lupus erythematosus. J Rheumatol 1994;21: 2231–8.PubMedGoogle Scholar
  96. 96.
    Sturgess AD, Evans DT, Mackay IR, Riglar A. Effects of the estrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 1984;13:11–14.PubMedGoogle Scholar
  97. 97.
    Lahita, RG, Kunkel HG. Treatment of systemic lupus erythematosus with the androgen 19-nortestosterone. Arthritis Rheum 1984;27:S65 (abstract).Google Scholar
  98. 98.
    Stroeber S, Field E, Hoppe RT et al. Treatment of intractable lupus nephritis with total lymphoid irradiation. Ann Intern Med 1985;102;450–8.Google Scholar
  99. 99.
    Strober S, Farinas MC, Field EH et al. Lupus nephritis after total lymphoid irradiation. Persistent improvement and reduction in steroid dosage. Ann Intern Med 1987;197:689–91.Google Scholar
  100. 100.
    Wacholtz MC, Lipsky PE. Treatment of lupus nephritis with CD5 PLUS, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain. Arthritis Rheum 1992;35:837–9.PubMedGoogle Scholar
  101. 101.
    Stafford, FJ, Fleisher TA, Brown M et al. Clinical and biological effects of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus (SLE). Arthritis Rheum 1993;36: S227.Google Scholar
  102. 102.
    Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9–13.PubMedGoogle Scholar
  103. 103.
    Austin HA, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544–50.PubMedGoogle Scholar
  104. 104.
    Esdaile JM. Prognosis in systemic lupus erythematosus. Springer Semin Immunopathol 1994; 16:337–55.PubMedGoogle Scholar
  105. 105.
    Levey AS, Lan S-P, Corwin HL et al. Lupus Nephritis Collaborative Study. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisolone and short-term oral cyclophosphamide. Ann Intern Med 1992;116:114–23.PubMedGoogle Scholar
  106. 106.
    Esdaile JM, Levington C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 1989;269:779–833.Google Scholar
  107. 107.
    Cheigh JS, Kim R, Stenzel KR et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990;16:189–95.PubMedGoogle Scholar
  108. 108.
    Cheigh JS, Stenzel KH. End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 1993;21:2–8.PubMedGoogle Scholar
  109. 109.
    Roth D, Milgrom M, Esquenazi V, Strauss J, Zilleruelo G, Miller J. Renal transplantation in systemic lupus erythematosus: one center’s experience. Am J Nephrol 1987;7:367–74.PubMedGoogle Scholar
  110. 110.
    Goss JA, Cole BR, Jendrisak MD et al. Renal transplantation in systemic lupus erythematosus and recurrent lupus nephritis: a single center experience and a review of the literature. Transplantation 1991;52:805–10.PubMedGoogle Scholar
  111. 111.
    Pollack CA, Ibels LS. Dialysis and transplantation in patients with renal failure due to systemic lupus erythematosus: the Australian and New Zealand experience. Aust NZ J Med 1987;17:321–5.Google Scholar
  112. 112.
    Wintrobe MM, Buell MV. Hyperproteinemia associated with multiple myeloma. Bull Johns Hopkins Hosp 1933;52:156–65.Google Scholar
  113. 113.
    Lerner AB, Watson CJ. Studies of cryoglobulins. I. Unusual purpura associated with the presence of high concentrations of cold precipitate serum globulin. Am J Med Sci 1947;214: 410–15.Google Scholar
  114. 114.
    Brouet JC, Clauvel JP, Danon F et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med1974;57;775–88.PubMedGoogle Scholar
  115. 115.
    Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia: a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966;40: 837–56.PubMedGoogle Scholar
  116. 116.
    Gorevic PD, Kassab HJ, Levo Y et al. Mixed cryoglobulinemia: clinical aspects and long term follow-up of 40 patients. Am J Med 1980;69:287–308.PubMedGoogle Scholar
  117. 117.
    Monti G, Galli M, Invernizzi F et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. Q J Med 1995;88: 115–26.Google Scholar
  118. 118.
    Winfield JB. Cryoglobulinemia. Hum Pathol 1983;14:350–4.PubMedGoogle Scholar
  119. 119.
    Geltner D, Kohn RW, Gorevic P, Franklin EC. The effect of combination therapy (steroids, immunosuppressives and plasmapheresis) on 5 mixed cryoglobulinaemia patients with renal, neurological and vascular involvement. Arthritis Rheum 1981;24:1121–7.PubMedGoogle Scholar
  120. 120.
    Tarantino A, De Vecchi A, Montagnino G et al. Renal disease in essential mixed cryoglobulinemia. Long-term follow up of 44 patients. Q J Med 1981; 197:1–30.Google Scholar
  121. 121.
    Ben-Bassat M, Boner G, Rosenfeld J et al. The clinco-pathologic features of cryoglobulinaemic nephropathy. Am J Clin Pathol 1983;79:147–56.PubMedGoogle Scholar
  122. 122.
    Cassuto-Viguier E, Quaranta JF, Ortonne JP, Cassuto JP, Duplay H, Dujardin P. Effect of plasma exchange on the course of cryoglobulinaemias. In: Nose Y, Malchevsky PS, Smith JW, Krakaw RSJW, Krakaw RS, editors. Plasmapheresis. New York: Raven Press; 1983:299–308.Google Scholar
  123. 123.
    L’Abbate A, Maggiore Q, Caccamo A, Bartolomeo F, Misefari V. Suppression of post-apheresis autoantibody rebound in cryoglobulinaemia and cold agglutinin haemolytic anaemia. Int JArtifOrg 1983;6:51–6.Google Scholar
  124. 124.
    Cordonnier DJ, Vialtel P, Dechelette E et al. Long-term management of essential mixed cryoglobulinaemia. In: Ponticelli C, Minetti L, D’Amico G, editors. Antiglobulins, Cryoglobulins and Glomerulonephritis. Dordrecht: Martinus Nijhoff; 1986:237–49.Google Scholar
  125. 125.
    Frankel AH, Singer DRJ, Winearls CG, Evans DJ, Rees AJ, Pusey CD. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992;298: 101–24.Google Scholar
  126. 126.
    Barbiano di Belgioioso G, Montoli A, Tarantino A et al. Clinical and histologic correlations in essential mixed cryoglobulinaemia glomerulonephritis. In: Ponticelli C, Minetti L, D’Amico G, editors. Antiglobulins, Cryoglobulins and Glomerulonephritis. Dordrecht: Martinus Nijhoff; 1986:203–10.Google Scholar
  127. 127.
    Tarantino A, Campise M, Banfi G et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618–23.PubMedGoogle Scholar
  128. 128.
    Ponticelli C, Imbasciati E, Tarantino A, Piertrogrande M. Acute anuric glomerulonephritis in monoclonal cryoglobulinemia. Br Med J 1977;1:948.PubMedGoogle Scholar
  129. 129.
    Lockwood CM. Lymphoma, cryoglobulinemia and renal disease. Kidney Int 1979;16:522–30.Google Scholar
  130. 130.
    Carlos HW, Tavassoli MD. Acute renal failure from precipitation of cryoglobulins in a cool operating room. J Am Med Assoc 1989;244:1472–3.Google Scholar
  131. 131.
    Druet P, Letonturier P, Contet A, Mandet C. Cryoglobulinemia in human renal disease: a study of 76 cases. Clin Exp Immunol 1969;15:483–96.Google Scholar
  132. 132.
    Ferrario F, Colasanti G, Barbiano Di Belgioioso G et al. Histological and immunohistological features in essential mixed cryoglobulinemia glomerulonephritis. In: Ponticelli C, Minetti L, D’Amico G, editors. Antiglobulins, Cryoglobulins and Glomerulonephritis. Dordrecht: Martinus Nijhoff; 1986:193–202.Google Scholar
  133. 133.
    Tarantino A, Moroni G, Banfi G, Manzoni C, Segagni S, Ponticelli C. Renal replacement therapy in cryoglobulinaemic nephritis. Nephrol Dial Transplant 1994;9:1426–30.PubMedGoogle Scholar
  134. 134.
    Macintosh RM, Kaufman DB, Kulvinskas C, Grossman B. Cryoglobulins. I. Studies on the nature, incidence, and clinical significance of serum cryoproteins in glomerulonephritis. J Lab Clin Med 1970;75:566–77.Google Scholar
  135. 135.
    Adam C, Morel-Maroger L, Richet G. Cryoglobulins in glomerulonephritis not related to systemic disease. Kidney Int 1973;3:334–41.PubMedGoogle Scholar
  136. 136.
    Feizi T, Gitlin N. Immune-complex disease of the kidney associated with chronic hepatitis and cryoglobulinemia. Lancet 1969;ii:873–6.Google Scholar
  137. 137.
    Cordonnier DD, Martin H, Groslambert P, Micouin C, Chenais F, Stoebner P. Mixed IgG-IgM cryoglobulinemia with glomerulonephritis. Immunochemical, fluorescent and ultra-structural study of kidney and in vitro cryoprecipitate. Am J Med 1975;59:867–72.PubMedGoogle Scholar
  138. 138.
    Feiner H, Gallo G. Ultrastructure in glomerulonephritis associated with cryoglobulinemia. AmJPathol 1977;88:145–62.Google Scholar
  139. 139.
    Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490–5.PubMedGoogle Scholar
  140. 140.
    Cacoub P, Musset L, Lunel Fabiani F et al. Hepatitis C virus and essential mixed cryoglobulinaemia. Br J Rheumatol 1993;32:689–92.PubMedGoogle Scholar
  141. 141.
    Realdi G, Alberti A, Rigoli A, Tremolada F. Immune-complexes and Australia antigen in cryoglobulinemic sera. Zimmunitatsforsch Exp Klin Immunol 1974;147:114–26.Google Scholar
  142. 142.
    Levo Y, Gorevic PD, Kassab HJ et al. Liver involvement in the syndrome of mixed cryoglobulinemia. Ann Intern Med1977;87:287–92.PubMedGoogle Scholar
  143. 143.
    Galli M, Careddu F, D’Armino A, Monti G, Messina K, Invernizzi F. Hepatitis B virus and essential mixed cryoglobulinemia. Lancet 1980;i: 1093.Google Scholar
  144. 144.
    Popp JJ, Dienstag JL, Wands JR, Bloch KJ. Essential mixed cryoglobulinemia without evidence for hepatitis B virus infection. Ann Intern Med 1980;92:379–83PubMedGoogle Scholar
  145. 145.
    Caporali R, Longhi M, Zorzoli I et al. Hepatitis B virus markers in monoclonal (type I and II) and polyclonal (type III) cryoglobulinemias. Haematologica 1988;73:375–8.PubMedGoogle Scholar
  146. 146.
    Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitic C virus in patients with cryoglobulinaemia type II. J Infect Dis 1990;162:569–70.PubMedGoogle Scholar
  147. 147.
    Ferri C, Greco F, Longombardo Get al. Antibodies against hepatitis C virus in mixed cryoglobulinemia patients. Infection 1991; 19:417–20.PubMedGoogle Scholar
  148. 148.
    Misiani R, Bellavita P, Fenili D et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573–7.PubMedGoogle Scholar
  149. 149.
    Ferri C, Marzo E, Longombardo G et al. Interferon-alpha in mixed cryoglobulinemia patients: randomized, crossover controlled trial. Blood 1993;81:1132–6.PubMedGoogle Scholar
  150. 150.
    Mazzaro C, Tulissi P, Moretti M et al. Clinical and virological findings in mixed cryoglobulinaemia. J Int Med 19 1995;238:153–60.Google Scholar
  151. 151.
    Sinico RA, Ribero ML, Fornasieri A et al. Hepatitis C virus genotype in patients with essential mixed cryoglobulinaemia. Q J Med 1995;88:805–10.Google Scholar
  152. 152.
    Sansonno D, Cornacchiulo V, lacobelli AR, Stefano RD, Lospalluti M, Dammacco F. Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinaemia. Hepatology 1995;21:305–12.PubMedGoogle Scholar
  153. 153.
    Lunel F, Musset L, Cacoub P et al. Cryoglobulinemia in chronic liver disease: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291–300PubMedGoogle Scholar
  154. 154.
    Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 1987;83:726–30.PubMedGoogle Scholar
  155. 155.
    Casuto M, Legana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-α for type II essential mixed cryoglobulinaemia. Blood 1991;78:3142–7.Google Scholar
  156. 156.
    Ferri C, Zignego AL, Longombardo G et al. Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. Infection 1993;2:93–6.Google Scholar
  157. 157.
    Misiani R, Bellavita P, Fenili D et al. Interferon alpha-2a therapy in cryoglobulinemia associated with Hepatitis C virus. N Engl J Med 1994;330:751–6.PubMedGoogle Scholar
  158. 158.
    Grossberg SE. An overview of their biological and biochemical properties. In: Pfeffer LM, editor. Mechanisms of Interferon Action. Boca Raton, FL: CRC; 1987:2.Google Scholar
  159. 159.
    Harfast B, Huddlestone JR, Casali P, Merigan TC, Oldstone MBA. Interferon acts directly on B lymphocytes to modulate immunoglobulin synthesis. J Immunol 1991;127:2146–50.Google Scholar
  160. 160.
    Exley R, Nathan P, Walker L, Gordon J, Clemens MJ. Antiproliferative effects of interferons on Daudi Burkitt-lymphoma cells: induction of cell differentiation and loss of response to autocrine growth factors. Int J Cancer 1987;40:53–9.PubMedGoogle Scholar
  161. 161.
    Dammacco F, Sansonno D, Han JH et al. Natural interferon-α versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long term, randomised, controlled study. Blood 1994;84:3336–43.PubMedGoogle Scholar
  162. 162.
    Johnson RJ, Gretch DR, Couser WGet al. Hepatitis C virus-associated glomerulonephritis. Effect of α-interferon therapy. Kidney Int 1994;46:1700–4.PubMedGoogle Scholar
  163. 163.
    Davis GL, Baiart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med 1989;321:1501–6.PubMedGoogle Scholar
  164. 164.
    Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321: 1506–10.PubMedGoogle Scholar
  165. 165.
    De Vecchi A, Montagnino G, Pozzi C, Locatelli F, Pontivelli C. Intravenous methylprednisolone therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 1983;5:221–7.Google Scholar
  166. 166.
    Vacca A, Dammacco F. Deflazacort versus prednisolone in the treatment of EMC: A between-patient controlled clinical study. Int Arch Allergy Immunol 1992;99;306–10.Google Scholar
  167. 167.
    Hippe E, Jensen KB, Olesen H, Lind K, Thomsen PEB. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood 1970;35:68–72.PubMedGoogle Scholar
  168. 168.
    Mathison DA, Condemi JJ, Leddy JP, Callerame ML, Panner BJ, Vaughan JH. Purpura, arthralgia, and IgM-IgG cryoglobulinemia with rheumatoid factor activity. Response to cyclophosphamide and splenectomy. Ann Intern Med 1971;74:383–90.PubMedGoogle Scholar
  169. 169.
    Grossman J, Abraham GN, Leddy JP. Crystalglobulinaemia. Ann Intern Med 1972;77:395–400.PubMedGoogle Scholar
  170. 170.
    Bengtsson U, Larsson O, Lindstedt G, Svalander C. Monoclonal IgG cryoglobulinemia with secondary development of glomerulonephritis and nephrotic syndrome. Q J Med 1975; 175: 491–503.Google Scholar
  171. 171.
    Martelo OJ, Schultz DR, Pardo V, Perez-Stable E. Immunologically-mediated renal disease in Waldenström’s macroglobulinemia. Am J Med1975;58:567–75.PubMedGoogle Scholar
  172. 172.
    Ristow SC, Griner PF, Abraham GN, Shoulson I. Reversal of systemic manifestations of cryoglobulinaemia. Arch Intern Med 1976; 136:467–70.PubMedGoogle Scholar
  173. 173.
    Ferri C, Gregmignai G, Bombardieri S et al. Plasma-exchange in mixed cryoglobulinemia. Effects on renal, liver and neurologic involvement. Ricerca Clin Lab 1986; 16:403–11.Google Scholar
  174. 174.
    Ferri C, Moriconi L, Gregmignai G et al. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986;43:246–53.PubMedGoogle Scholar
  175. 175.
    Cordonnier D, Vialtel P, Renversez J et al. Renal diseases in 18 patients with mixed type II IgM-IgG cryoglobulinaemia: monoclonal lymphoid infiltration (2 cases) and membranopro-liferative glomerulonephritis (14 cases). Adv Nephrol 1983; 12:177–204.Google Scholar
  176. 176.
    Sinico R, Fornasieri A, Fiorini G et al. Plasma exchange in glomerulonephritis associated with systemic lupus erythematosus and essential mixed cryoglobulinaemia. Int J Artif Org 1983;6:21–5.Google Scholar
  177. 177.
    Maggiore Q, L’Abbate A, Bartolomeo F, Martorano C, Cutrupi S. Effects of cryoapheresis on plasma cryoglobulins and renal function in patients with EMC glomerulonephritis. In: Ponticelli C, Minetti L, D’Amico G, editors. Antiglobulins, Cryoglobulins and Glomerulonephritis. Dordrecht: Martinus Nijhoff; 1986:251–64.Google Scholar
  178. 178.
    Houwert DA, Hene RJ, Struyvenberg A, Kater L. Effect of plasmapheresis (PP), corticoster-oids and cyclophosphamide in essential mixed cryoglobulinaemia associated glomerulone-phritis. Proc EDTA 1980; 17:650–4.Google Scholar
  179. 179.
    D’Amico G, Colasanti G, Ferrario F, Sinico RA. Renal involvement in essential mixed cryoglobulinemia. Kidney Int 1989;35:1004–14.PubMedGoogle Scholar
  180. 180.
    Tarantino A, Montagnino G, Baldasarri A et al. Prognostic factors in essential mixed cryoglobulins and glomerulonephritis. In: Ponticelli C, Minetti L, D’Amico G, editors. Antiglobulins, Cryoglobulins and Glomerulonephritis. Dordrecht: Martinus Nijhoff; 1986: 219–25.Google Scholar
  181. 181.
    Andrejak M, Bariety J, Bedrossian J et al. Cryoglobulinaemia in renal transplant recipients. Transplantation 1978;26:446–7.PubMedGoogle Scholar
  182. 182.
    Hiesse C, Bastuji-Garin S, Santelli Get al. Recurrent essential mixed cryoglobulinemia in renal allografts. Am J Nephrol 1989;9:150–4.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Wai Y. Tse
  • D. Adu

There are no affiliations available

Personalised recommendations